$ETTX News

Last published 11mo ago

11mo agoETTXApproval of Nuzolvence, Nda #219491 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 12/12/2025; Drug Name: Nuzolvence, Nda #219491; Active Ingredients: ZOLIFLODACIN; Company: Entasis Therap; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 219491
3y agoETTXApproval of Xacduro, Nda #216974 (Type 1 - New Molecular Entity and Type 4 - New Combination)FDA Approved DrugsApproval Date: 05/23/2023; Drug Name: Xacduro, Nda #216974; Active Ingredients: SULBACTAM;DURLOBACTAM; Company: Entasis Therapeutics Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity and Type 4 - New Combination; Application Number: 216974
4y agoETTX INVAEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022GlobeNewswireWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly
4y agoETTX INVAInnoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.Business WireInnoviva, Inc. (NASDAQ:INVA) ("Innoviva") today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ("Entasis") at a price of $2.20 per share, net to t
4y agoETTXEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceGlobeNewswireWALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple pres
4y agoETTX INVAInnoviva to Acquire Entasis TherapeuticsGlobeNewswireInnoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis' closing price of $1.47 per share on January 31, 2022, the last date before Innoviva's
4y agoETTX INVAInnoviva to Acquire Entasis TherapeuticsBusiness WireInnoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis' closing price of $1.47 per share on January 31, 2022, the last date before Innov
4y agoETTXEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceGlobeNewswireWALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the compan
4y agoARMP ETTX INVAInnoviva Reports First Quarter 2022 Financial ResultsBusiness WireRoyalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. In
4y agoETTXEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireHighlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conference SUL-DUR NDA submission on track for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 20
4y agoETTXEntasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 ConferenceGlobeNewswireWALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that top-line
4y agoETTXEntasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 ConferenceGlobeNewswireWALTHAM, Mass., April 18, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the comp
4y agoETTX ZLABEntasis Therapeutics Announces Year End 2021 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 ATTACK registrational trial for sulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints, NDA submission planned for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 Entasis' pa
4y agoETTXEntasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.GlobeNewswireWALTHAM, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that its Board of D
4y agoETTXEntasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022GlobeNewswireWALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Compa
5y agoETTX ZLABEntasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireSulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trial Robust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatme
5y agoETTXEntasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021GlobeNewswireWALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that managemen
5y agoETTX ZLABZai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK TrialGlobeNewswireSUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at Test of Cure vs. colistin Favorable safety profile wit
5y agoBMRA ETTX PRLD RKLY+1Thinking about buying stock in Energous Corp, Entasis Therapeutics, Prelude Therapeutics, Biomerica, or Rockley Photonics?PR NewswireNEW YORK, Oct. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, ETTX, PRLD, BMRA, and RKLY.
5y agoETTXEntasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trialGlobeNewswireSUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at Test of Cure vs. colistin Favorable safety profile with s
5y agoETTXEntasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management wi
5y agoETTXProfile of Entasis Therapeutics ETX0462 Candidate Published in the Journal NatureGlobeNewswireWALTHAM, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of
5y agoETTXEntasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireWALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management wi
5y agoETTX INVA ZLABEntasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswire-Management to Host Conference Call on August 12 at 8am ET- Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021 SUL-DUR Launch Planning Progresses with Appointment of Anna
5y agoETTXEntasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021GlobeNewswireWALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management wil
5y agoETTXEntasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of manageme
5y agoETTX INVAInnoviva Reports Second Quarter 2021 Financial ResultsBusiness WireRoyalties increased by 44% to $104.3 million in the second quarter of 2021, compared to the same quarter in 2020. Repurchased GSK's full 32% equity stake in Innoviva for $392 million purchase price. Strategically invested an additional $20 mil
5y agoETTX ZLABEntasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-DurlobactamGlobeNewswire– First clinical trial to specifically study confirmed carbapenem-resistant Acinetobacter infections– – Phase 3 top-line data readout now anticipated in early 4Q 2021 – WALTHAM, Mass. and SHANGHAI, Chi
5y agoETTXEntasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial OfficerGlobeNewswire– Significant commercial strategy and product launch experience –– ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 – WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clin
5y agoETTXEntasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat PathogensGlobeNewswireWALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of
5y agoCLNE EDU ETTX GEO+1Thinking about buying stock in The GEO Group, Palantir Technologies, Entasis Therapeutics, Clean Energy Fuels, or New Oriental Education?PR NewswireNEW YORK, June 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEO, PLTR, ETTX, CLNE, and EDU. To
5y agoETTXEntasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe ForumGlobeNewswireWALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentati
5y agoETTX INVA ZLABEntasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswire– ATTACK Phase 3 topline data readout remains on track for second half of 2021 – – Strengthened balance sheet with $20M financing – WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc.
5y agoETTX INVAEntasis Therapeutics Completes Initial Closing of $20M Private Placement with InnovivaGlobeNewswireWALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has complete
5y agoETTXEntasis Therapeutics Reports Full Year 2020 Financial Results and Provides Business UpdateGlobeNewswire– Phase 3 ATTACK registration trial more than three-quarters complete –– ATTACK topline data readout expected second half of 2021 –– Zoliflodacin Phase 3 trial adds clinical trial sites, continues...
5y agoETTXEntasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.GlobeNewswireWALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
5y agoETTXEntasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 ConferenceGlobeNewswireWALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
5y agoETTXEntasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare SymposiumGlobeNewswireWALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
6y agoETTXEntasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business UpdateGlobeNewswireWALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
6y agoETTXEntasis Therapeutics Highlights Multiple Data Presentations at Virtual ID WeekGlobeNewswireWALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
6y agoETTXEntasis Therapeutics to Participate in Upcoming Healthcare Investor ConferencesGlobeNewswireWALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
6y agoETTXEntasis Therapeutics Announces $25 Million Private PlacementGlobeNewswireWALTHAM, Mass., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development...
6y agoETTXEntasis Therapeutics Reports Second Quarter 2020 Financial Results and Business UpdateGlobeNewswireWALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
6y agoETTXEntasis Therapeutics to Participate in Upcoming Healthcare ConferencesGlobeNewswireWALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
6y agoETTXEntasis Therapeutics Awarded Contract from National Institutes of HealthGlobeNewswireWALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
6y agoETTXEntasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with InnovivaGlobeNewswireWALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development...
6y agoINVA ETTXInnoviva Reports First Quarter 2020 Financial ResultsBusiness WireBURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ:INVA) ("Innoviva," or "the Company") today reported financial results for the first quarter ended March 31, 2020.
6y agoETTXEntasis Therapeutics Completes Initial Closing of $35M Private Placement with InnovivaGlobeNewswireWALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development...
6y agoETTXEntasis Therapeutics Reports Full Year 2019 Financial Results and Business UpdateGlobeNewswireWALTHAM, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
7y agoCDTX ETTX ITRM MLNT+4Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019PR NewswireThe Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving...